There is a major therapeutic benefit in understanding what you’ve got, believing you will do well, and trusting the team that is treating you.
Originally from Nova Scotia, Canada, Dr. Maher holds a bachelor's degree in biology from Amherst College in Massachusetts, where she graduated cum laude. she completed her postdoctorate degree in physiology at Mcgill University in Montreal. She then earned her medical degree at McGill University. She completed internal medicine residency training at the University of Toronto.
Dr. Maher completed multiple fellowships during her career. She did fellowships in hematology and oncology and internal medicine at Harvard Medical School, a fellowship in the Hypertension Research Unit at the University of Medicine and Dentistry of New Jersey, a neurology fellowship at the Children's Hospital of Boston, a fellowship in physiology at McGill University, and a fellowship in adult oncology at the Dana-Farber Cancer Institute at Harvard Medical School.
Certified by the American Board of Internal Medicine in medical oncology, Dr. Maher joined the UT Southwestern faculty in 2006. She is now the Director of Translational Research for the Neuro-Oncology Program at UT Southwestern and the Director of the Crystal Ball Charity Center for Pediatric Brain and Neurological Diseases.
At UT Southwestern, Dr. Maher is a member of the Supporting Women Achieving Greatness (SWAG) Committee and the Charles Y.C. and Jane Pak Breast Cancer - Bon Initiative Advisory Committee.
Dr. Maher is a member of several professional societies, including the American Society of Clinical Oncology, the Society of Neuro-Oncology, and the American Association of Cancer Research.
- Other Post Graduate Training
- McGill University Faculty of Medicine (1989)
- Graduate School
- McGill University Faculty of Medicine (1989), Physiology
- Medical School
- McGill University Faculty of Medicine (1993)
- University of Toronto Hospitals, Canada (1996), Internal Medicine
- Dana-Farber Cancer Institute (1999), Hematology Oncology
- Development of improved imaging techniques for brain tumors
- Primary and metastatic brain tumors
- Role of altered metabolism in the progression of malignant gliomas.
- Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
- Cai Q, Li X, Xiong H, Fan H, Gao X, Vemireddy V, Margolis R, Li J, Ge X, Giannotta M, Hoyt K, Maher EA, Bachoo R, Qin Z Nature communications 2023 Dec 14
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
- Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF Nature medicine 2023 Mar 29 615-622
- Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
- Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Dan TD, Patel TR, Vo DT Discover Oncology 2022 Dec 13
- Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients
- Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Lee M, Dan TD, Patel TR, Vo DT Frontiers in Oncology 2022 Sep 12
- Primary central nervous system lymphoma: A real-world comparison of therapy access and outcomes by hospital setting
- Patel AM, Ali O, Kainthla R, Rizvi SM, Awan FT, Patel T, Pan E, Maher E, Desai NB, Timmerman R, Kumar KA, Ramakrishnan Geethakumari P Neuro-Oncology Practice 2022 May 9 183-192
- Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate
- Ganji SK, An Z, Tiwari V, Chang Y, Patel TR, Maher EA, Choi C Magnetic resonance in medicine 2022 Mar 87 1150-1164
- Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm
- Askari P, Dimitrov IE, Ganji SK, Tiwari V, Levy M, Patel TR, Pan E, Mickey BE, Malloy CR, Maher EA, Choi C Magnetic resonance in medicine 2021 Oct 86 1818-1828
- Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human phase I trial
- Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY Clinical Cancer Research 2021 Aug 27 4491-4499
- Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma
- Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY Journal of Clinical Oncology 2020 Oct 38 3398-3406
- In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients
- Tiwari V, Mashimo T, An Z, Vemireddy V, Piccirillo S, Askari P, Hulsey KM, Zhang S, de Graaf RA, Patel TR, Pan E, Mickey BE, Maher EA, Bachoo RM, Choi C Magnetic resonance in medicine 2020 Sep 84 1152-1160
- American Society of Clinical Oncology (2001)
- Society for Neuro-Oncology (2003)